ALS News Today – FDA, PharmAust to meet over plans for Phase 2/3 trial of monepantel MediaBy Nickholas Bahr09/01/2024
Stockhead – PharmAust just got a pre-IND meeting with the US FDA to kick off ‘24 MediaBy Nickholas Bahr02/01/2024
Stockhead – Santa (and ATO) delivers PharmAust $550k cash boost for Christmas MediaBy Nickholas Bahr30/12/2023
The Advertiser – (More) ASX biotechs with catalysts that could make them pop in 2024 MediaBy Nickholas Bahr29/12/2023
Stockhead – Up to $1.8m funding from motor neurone disease foundation could be on the table for PharmAust MediaBy Nickholas Bahr22/12/2023
Stockhead – Prominent Perth fundie the main backer in PharmAust’s $3.5m cap raise MediaBy Nickholas Bahr13/12/2023
Small Caps – PharmAust adds highly-credentialled members to management team MediaBy Nickholas Bahr06/12/2023
Stockhead – Why this ASX biotech is primed to capitalise as big pharma flocks to the rare diseases market MediaBy Nickholas Bahr22/11/2023
The Australian – Results from 11 of 12 patients in PharmAust trial point to stabilised MND progression MediaBy Nickholas Bahr24/08/2023
